Teclistamab in Previously Treated AL Amyloidosis

Who May Qualify: - Biopsy confirmed AL amyloidosis - Patients must have received at least one line of treatment, including daratumumab and bortezomib - Relapse from previous treatment, or less than partial response after two cycles of treatment/less than very good partial response after three cycles of treatment - dFLC \> 50mg/L Who Should NOT Join This Trial: - Previous anti-BCMA targeted therapy - Co-morbidity of uncontrolled infection - Co-morbidity of other active malignancy - Co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia - Co-morbidity of grade 2 Mobitz II or grade 3 atrioventricular block (expect for those with implanted pacemaker) - Co-morbidity of sustained or recurrent nonsustained ventricular tachycardia - Seropositive for human weakened immune system virus - Hepatitis B virus (HBV)-DNA \> 1000 copies/mL - Seropositive for hepatitis C (except in the setting of a sustained virologic response) - Neutrophil \<1×10E9/L, hemoglobin \< 8g/dL, or platelet \< 75×10E9/L. - Severely compromised hepatic or renal function: alanine transaminase (ALT) or aspertate aminotransferase (AST) \> 5 × upper limit of normal (ULN), total bilirubin \> 2 × ULN, eGFR \< 20 mL/min, or receiving renal replacement therapy Always talk to your doctor about whether this trial is right for you.